Takeda, Seattle Genetics Drug Shown Effective Against Lymphoma
This article was originally published in PharmAsia News
Takeda Pharmaceutical and U.S.-based Seattle Genetics plan to ask the FDA for accelerated approval of their Hodgkin's lymphoma drug based on better-than-expected trial results and the fact that it addresses an unmet medical need
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?